Kitty Yale

Chief Development Officer

Kitty Yale is Chief Development Officer of Akero Therapeutics. Kitty joins Akero from Gilead Sciences, where she led global clinical operations and management of the company’s oncology, HIV, inflammation, and liver disease trials, and held senior clinical research and operations roles at Gilead and Roche Global Development. As VP of Clinical Operations at Gilead, her most recent role prior to joining Akero, Kitty led global development programs resulting in eight drug approvals in the US, EMEA, Canada, Korea, Japan, and China.